ANI Pharmaceuticals EBIT

The latest EBIT for ANIP is $150M as of June 2026. That compares with $5.3M in the prior-year period — up 2811.8% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside ANI Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANIP's EBIT moved from $5.3M to $150M — a 2811.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ANI Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ANIP currently prints $150M for EBIT, while the sector average sits near $23B. That is roughly 99.3% below the sector mean. Large gaps often invite a closer look at ANI Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $150M for ANIP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ANIP's EBIT ($150M), review year-over-year change from $5.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.